Archives of Advances in Biosciences

Vol. 16 No. 1 (2025)

Simultaneous Inhibition of Histone Deacetylases and EZH2 Reduces SASP in Non-Small Cell Lung Cancer

Archives of Advances in Biosciences, Vol. 16 No. 1 (2025), 2 March 2025 , Page 1-10
https://doi.org/10.22037/aab.v16i1.51195

Abstract

Background and Aim: Cellular senescence, a common outcome of treatments like chemotherapy and radiotherapy, often acts as a therapeutic hurdle. Our prior investigations revealed that this senescent state is accompanied by the secretion of the senescence-associated secretory phenotype (SASP), a potent driver of chronic inflammation and a factor that can paradoxically facilitate tumor progression.

Methods: We investigated the effects of SAHA, alone or combined with the EZH2 inhibitor EPZ-6438, on NSCLC cell lines. Senescence induction was confirmed via SA-β-galactosidase staining, while cell growth was evaluated using MTT and colony formation assays. Mechanistic studies, including Western blotting, qPCR for SASP factors, and immunofluorescence for Cytoplasmic Chromatin Fragments (CCF), were performed to assess the underlying pathway.

Results: SAHA effectively induced senescence-mediated growth inhibition in A549 and H1299 cells but simultaneously triggered the SASP. This SAHA-induced SASP was linked to the generation of CCFs, thereby activating the cGAS–STING pathway. Importantly, the combined administration of SAHA and EPZ-6438 significantly reduced the expression of inflammatory mediators, such as IL6 and IL8. This co-treatment not only provided superior anti-proliferative activity compared to SAHA alone but also enhanced the suppression by attenuating the SASP.

Conclusion: Collectively, our data demonstrate that SAHA-induced senescence in NSCLC cells is critically linked to detrimental SASP production mediated by CCF formation. Crucially, combining SAHA with EZH2 inhibition successfully suppressed the SASP, leading to enhanced growth inhibition, thereby providing a robust rationale for this combination therapy in NSCLC treatment.

Keywords:
  • Non small cell lung cancer
  • Suberoylanilide Hydroxamic Acid
  • Enhancer of zeste homolog
  • senescence
  • senescence associated secretory phenotype

How to Cite

Kim, H.-S., Kong, S.-H., Pak, C.-J., Jang, J.-C., Ri, B.-S., Ri, K.-C., … Ri, U. S. (2026). Simultaneous Inhibition of Histone Deacetylases and EZH2 Reduces SASP in Non-Small Cell Lung Cancer. Archives of Advances in Biosciences, 16(1), 1–10. https://doi.org/10.22037/aab.v16i1.51195

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021 Jan;71(1):7–33. (DOI: 10.3322/caac.21654) (PMID)

2. Duruisseaux M, Esteller M. Lung cancer epigenetics: From knowledge to applications. Semin Cancer Biol. 2018 Aug;51:11628. (DOI: 10.1016/j.semcancer.2017.09.005) (PMID)

3. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine. 2005 Mar; 2(3):e73. (DOI: 10.1371/journal.pmed.0020073) (PMID)

4. Wang B, Kohli J, Demaria M. Senescent Cells in Cancer Therapy: Friends or Foes? Trends in Cancer. 2020 Oct;6(10):838-57. (DOI: 10.1016/j.trecan.2020.05.004) (PMID)

5. Demaria M, O'Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discovery. 2017 Feb;7(2):165-76. (DOI: 10.1158/2159-8290.CD-16-0241) (PMID)

6. Lecot P, Alimirah F, Desprez PY, Campisi J, Wiley C. Context-dependent effects of cellular senescence in cancer development. British Journal of Cancer. 2016 May;114(11):1180-4. (DOI: 10.1038/bjc.2016.115) (PMID)

7. Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019 Oct;179(4):813-27. (DOI: 10.1016/j.cell.2019.10.005) (PMID)

8. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Review of Pathology. 2010;5:99-118. (DOI: 10.1146/annurev-pathol-121808-102144) (PMID)

9. Lederle W, Depner S, Schnur S, Obermueller E, Catone N, Just A, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. International Journal of Cancer. 2011 Jun;128:2803-14. (DOI: 10.1002/ijc.25621) (PMID)

10. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Research. 2013 Jun;73:3470-3480. (DOI: 10.1002/ijc.25621) (PMID)

11. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene. 2011 May;30:2345-55. (DOI: 10.1038/onc.2010.605) (PMID)

12. Song L, Rawal B, Nemeth J A, et al. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Molecular Cancer Therapeutics. 2011 Mar;10(3):481-94. (DOI: 10.1158/1535-7163.MCT-10-0502) (PMID)

13. Oubaha M, Miloudi K, Dejda A, Guber V, Mawambo G, Germain MA, et al. Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy. Science Translational Medicine. 2016 Oct;8(362):362ra144. (DOI: 10.1126/scitranslmed.aaf9440) (PMID)

14. Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, et al. Lysosome-mediated processing of chromatin in senescence. Journal of Cell Biology. 2013 Jul;202(1):129-43. (DOI: 10.1083/jcb.201212110) (PMID)

15. Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017 Oct;550(7676):402-6. (DOI: 10.1038/nature24050) (PMID)

16. Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proceedings of the National Academy of Sciences of USA. 2017 Jun;114(23):E4612-E20. (DOI: 10.1073/pnas.1705499114) (PMID)

17. Glück S, Guey B, Gulen MF, Wolter K, Kang TW, Schmacke NA, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nature Cell Biology. 2017 Sep;19(9):1061-70. (DOI: 10.1038/ncb3586) (PMID)

18. Krupina K, Goginashvili A, Cleveland DW. Causes and consequences of micronuclei. Current Opinion in Cell Biology. 2021 Jun;70:91-9. (DOI: 10.1016/j.ceb.2021.01.004) (PMID)

19. Fardi M, Solali S, Farshdousti Hagh M. Epigenetic mechanisms as a new approach in cancer treatment: An updated review. Genes & Diseases. 2018 Jun;5(4):304-11. (DOI: 10.1016/j.gendis.2018.06.003) (PMID)

20. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004 May;5(5):455-63. (DOI: 10.1016/s1535-6108(04)00114-x) (PMID)

21. Ropero S, Fraga M F, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics. 2006 May;38(5):566-9. (DOI: 10.1038/ng1773) (PMID)

22. Li Z, Zhu W G. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. International Journal of Biological Sciences. 2014 Jul;10(7):757-70. (DOI: 10.7150/ijbs.9067) (PMID)

23. Almeida LO, Guimarães DM, Martins MD, Martins MAT, Warner KA, Nör JE, et al. Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence. Stem Cell Research. 2017 May;21:94-105. (DOI: 10.1016/j.scr.2017.04.003) (PMID)

24. Duan D, Shang M, Han Y, Liu J, Liu J, Kong SH, Hou J, et al. EZH2–CCF–cGAS Axis Promotes Breast Cancer Metastasis. International Journal of Molecular Sciences. 2022 Feb;23(3):1788. (DOI: 10.3390/ijms23031788) (PMID)

25. Kong SH, Ma L, Yuan Q, Liu X, Han Y, Xiang W, et al. Inhibition of EZH2 alleviates SAHA-induced senescenceassociated secretion phenotype in small cell lung cancer cells. Cell Death Discovery. 2023 Aug;9(1):289. (DOI: 10.1038/s41420-023-01591-y) (PMID)

26. Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends in Cell Biology. 2018 Jun;28(6):436-53. (DOI: 10.1016/j.tcb.2018.02.001) (PMID)

27. Kumari R, Jat P. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Frontiers in Cell and Developmental Biology. 2021 Mar;9:645593. (DOI: 10.3389/fcell.2021.645593) (PMID)

28. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clinical Cancer Research. 2013 Dec;19:6556–65. (DOI: 10.1158/1078-0432.CCR-12-3946) (PMID)

29. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. Journal of the National Cancer Institute. 2010 Oct;102(20):1536-46. (DOI: 10.1093/jnci/djq364) (PMID)

30. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. Journal of Biological Chemistry. 2012 Nov;287(47):39776-88. (DOI: 10.1074/jbc.M112.382986) (PMID)

31. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature Reviews Cancer. 2006 Nov;6(11):846–56. (DOI: 10.1038/nrc1991) (PMID)

32. Zhang JX, Chen LY, Han L, Shi ZD, Zhang JN, Pu PY, et al. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Letters. 2015 Jan;356(2 Pt B):929-36. (DOI: 10.1016/j.canlet.2014.11.003) (PMID)

33. Kim KH, Roberts CW. Targeting EZH2 in cancer. Natature Medicine. 2016 Feb;22(2):128-34. (DOI: 10.1038/nm.4036) (PMID)

  • Abstract Viewed: 141 times
  • PDF Downloaded: 27 times

Download Statastics

Developed By

Open Journal Systems

Information